Processing...
Clinical Trials for Mesothelioma
Search
Search
There are 30 active trials for advanced/metastatic mesothelioma.
Click on a trial to see more information.
30 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with mesothelin-expressing recurrent/relapsed advanced ovarian (including primary peritoneal/fallopian tube), cholangiocarcinoma, or epithelial mesothelioma (pleural/peritoneal), ECOG 0–1, after ≥1 prior therapy, receive lymphodepleting chemotherapy followed by a single infusion of SynKIR-110, an autologous T-cell therapy using a mesothelin-targeted KIR-CAR (activating KIR plus DAP12) designed to enhance persistence/function in solid tumors. Excludes prior gene-engineered T-cell therapy, sarcomatoid/biphasic mesothelioma, active viral infections, significant pulmonary disease, and active autoimmune disease.
ClinicalTrials.gov ID: NCT05568680
TrialFetch AI summary: Adults with advanced solid tumors; dose escalation includes refractory/metastatic tumors (notably malignant mesothelioma and epithelioid hemangioendothelioma), with expansion for mesothelioma, EHE regardless of Hippo status, and other tumors harboring Hippo pathway alterations. Patients receive oral BGC515, a covalent pan‑TEAD1–4 inhibitor targeting the Hippo/YAP–TAZ transcriptional pathway, once daily in 21‑day cycles.
ClinicalTrials.gov ID: NCT06452160
TrialFetch AI summary: Children and young adults with relapsed/refractory pediatric-type solid tumors (non-CNS) receive cyclophosphamide/etoposide lymphodepletion followed by a single infusion of ex vivo expanded, cord blood–derived allogeneic NK cells (4–6/6 HLA-matched donor). The NK cells are activated to enhance MHC-unrestricted cytotoxicity (via natural cytotoxicity receptors and ADCC) to assess safety, dosing, persistence, and preliminary antitumor activity.
ClinicalTrials.gov ID: NCT03420963
TrialFetch AI summary: Adults with unresectable advanced/metastatic malignant mesothelioma (post–platinum and checkpoint inhibitor) or other solid tumors, with Part 2 requiring documented Hippo pathway dysregulation for non-mesothelioma, receive once-daily oral ISM6331 monotherapy. ISM6331 is a small‑molecule, non‑covalent pan‑TEAD (TEAD1–4) inhibitor targeting the TEAD palmitoylation pocket to suppress YAP/TAZ–TEAD transcription in Hippo-dysregulated tumors.
ClinicalTrials.gov ID: NCT06566079
TrialFetch AI summary: Adults with metastatic or unresectable solid tumors after standard therapy, enriched for mesothelioma and cancers with Hippo pathway alterations (e.g., NF2, LATS1/2, FAT1, YAP/TAZ fusions), receive continuous oral SW-682. SW-682 is a selective pan‑TEAD inhibitor targeting the TEAD palmitoylation pocket to disrupt YAP/TAZ‑TEAD transcription; dose-escalation/expansion includes histology/genomic cohorts and a planned combination-therapy cohort.
ClinicalTrials.gov ID: NCT06251310
TrialFetch AI summary: Adults and adolescents (16–80 years) with CD70-positive advanced clear cell RCC (post PD-1/PD-L1 and anti-angiogenic therapy), mesothelioma (progressive after standard options including checkpoint blockade), or osteosarcoma (recurrent/refractory after anthracycline) receive fludarabine/cyclophosphamide lymphodepletion followed by a single infusion of allogeneic cord blood–derived CAR NK cells targeting CD70 via a CD27-based CAR, armored with IL-15 for persistence and containing an inducible caspase-9 safety switch. Single-arm dose-escalation/expansion evaluates safety, dose, persistence, and preliminary activity.
ClinicalTrials.gov ID: NCT05703854
TrialFetch AI summary: The trial investigates the use of AG01, an anti-progranulin/GP88 monoclonal antibody, in patients with relapsed or refractory advanced solid tumors, including triple negative breast cancer, hormone-resistant breast cancer, non-small cell lung cancer, and mesothelioma, who have no remaining effective treatment options. AG01 is administered biweekly to evaluate its safety, tolerability, and preliminary anti-tumor activity.
ClinicalTrials.gov ID: NCT05627960
TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors or diffuse large B-cell lymphoma who have exhausted standard therapies, evaluating the investigational oral CBL-B inhibitor NX-1607 (which enhances antitumor immunity by blocking a negative regulator of immune cell activation) as monotherapy or in combination with paclitaxel. Eligible tumor types include ovarian, gastric, head and neck, melanoma, NSCLC, prostate, mesothelioma, triple-negative breast, urothelial, cervical, microsatellite-stable colorectal cancer, and DLBCL/Richter transformation.
ClinicalTrials.gov ID: NCT05107674
TrialFetch AI summary: This trial enrolls adults with advanced solid tumors or lymphoma that are refractory to standard therapies, whose tumors overexpress TrkA or harbor an NTRK1 gene fusion, to receive oral VMD-928, a highly selective irreversible TrkA inhibitor that acts via allosteric dimerization and inactivation of the target. Key exclusions include significant comorbidities and impaired drug absorption.
ClinicalTrials.gov ID: NCT03556228
TrialFetch AI summary: This trial enrolls adults with selected advanced solid tumors—including NSCLC, renal cell carcinoma, melanoma, platinum-resistant ovarian cancer, nasopharyngeal carcinoma, and triple negative breast cancer—who have progressed after specific prior therapies, to evaluate the safety and dosing of KFA115 (a novel immunomodulatory small molecule, presumed to enhance anti-tumor immunity) as monotherapy and in combination with pembrolizumab. Exclusion criteria include significant cardiac, autoimmune, and interstitial lung diseases, as well as history of severe hypersensitivity to study drugs.
ClinicalTrials.gov ID: NCT05544929